^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MCL1 expression

    i
    Other names: MCL1, MCL1 Apoptosis Regulator BCL2 Family Member, Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1, Myeloid Cell Leukemia Sequence 1 (BCL2-Related), MCL1 BCL2 Family Apoptosis Regulator, Bcl-2-Related Protein EAT/Mcl1, Myeloid Cell Leukemia 1, Bcl-2-Like Protein 3, Bcl2-L-3, Mcl1/EAT, BCL2L3, BCL2 Family Apoptosis Regulator, Myeloid Cell Leukemia ES, MCL1-ES, MCL1L, MCL1S, Mcl-1, EAT, TM
    Entrez ID:
    4170
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (NCT01303341)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/27/2023
    Initiation :
    02/18/2011
    Primary completion :
    05/01/2012
    Completion :
    09/09/2023
    BCL2 • MCL1 • BCL2L11
    |
    BCL2 expression • MCL1 expression
    |
    sorafenib • riluzole
    Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL (NCT03319901)
    Phase 1/2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    10/05/2022
    Initiation :
    10/30/2017
    Primary completion :
    04/30/2023
    Completion :
    04/30/2025
    BCL2 • MCL1 • BCL2L1 • BAD • BBC3
    |
    BCL2 expression • MCL1 expression
    |
    Venclexta (venetoclax) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies (NCT01188252)
    Phase 1
    Bayer
    Completed
    Last update posted :
    01/09/2017
    Initiation :
    08/01/2010
    Primary completion :
    06/01/2016
    Completion :
    12/01/2016
    CASP3 • ANXA5 • CDKN1A
    |
    MCL1 expression
    |
    roniciclib (BAY1000394)
    Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00735930)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    04/02/2015
    Initiation :
    08/01/2008
    Primary completion :
    03/01/2013
    Completion :
    11/01/2014
    BCL2 • IL6 • STAT3 • FAS • CD40 • CD80 • CD86
    |
    MCL1 expression
    |
    lenalidomide • alvocidib (DSP-2033)